Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction

Ke Cheng, Ahmed Ibrahim, M. Taylor Hensley, Deliang Shen, Baiming Sun, Ryan Middleton, Weixin Liu, Rachel R. Smith, Eduardo Marbán

Research output: Contribution to journalArticle

Abstract

Background-The regenerative potential of cardiosphere-derived cells (CDCs) for ischemic heart disease has been demonstrated in mice, rats, pigs, and a recently completed clinical trial (CADUCEUS). CDCs are CD105+ stromal cells of intrinsic cardiac origin, but the antigenic characteristics of the active fraction remain to be defined. CDCs contain a small minority of c-kit+ cells, which have been argued to be cardiac progenitors, and a variable fraction of CD90+ cells whose bioactivity is unclear. Methods-We performed a retrospective analysis of data from the CADUCEUS trial and a prospective mouse study to elucidate the roles of c-kit+ and CD90+ cells in human CDCs. Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit+ cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). In contrast, CD90 expression negatively correlates with the therapeutic benefit of CDCs in humans (ie, higher CD90 expression associated with lower efficacy). Depletion of CD90+ cells augments the functional potency of CDCs in murine MI. CD90- CDCs secrete lower levels of inflammatory cytokines and can differentiate into cardiomyocytes in vitro and in vivo. Conclusion-The majority population of CDCs (CD105+/CD90-/c-kit-) constitutes the active fraction, both in terms of therapeutic efficacy and in the ability to undergo cardiomyogenic differentiation. The c-kit+ fraction is neither necessary for, nor contributory to, the regenerative efficacy of CDCs.

Original languageEnglish (US)
Article numbere001260
JournalJournal of the American Heart Association
Volume3
Issue number5
StatePublished - 2014
Externally publishedYes

Fingerprint

Myocardial Infarction
Stromal Cells
Cardiac Myocytes
Myocardial Ischemia
Swine
Therapeutics
Clinical Trials
Prospective Studies
Cytokines

Keywords

  • Cardiosphere-derived cells
  • CD90
  • Ckit
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. / Cheng, Ke; Ibrahim, Ahmed; Hensley, M. Taylor; Shen, Deliang; Sun, Baiming; Middleton, Ryan; Liu, Weixin; Smith, Rachel R.; Marbán, Eduardo.

In: Journal of the American Heart Association, Vol. 3, No. 5, e001260, 2014.

Research output: Contribution to journalArticle

Cheng, K, Ibrahim, A, Hensley, MT, Shen, D, Sun, B, Middleton, R, Liu, W, Smith, RR & Marbán, E 2014, 'Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction', Journal of the American Heart Association, vol. 3, no. 5, e001260.
Cheng, Ke ; Ibrahim, Ahmed ; Hensley, M. Taylor ; Shen, Deliang ; Sun, Baiming ; Middleton, Ryan ; Liu, Weixin ; Smith, Rachel R. ; Marbán, Eduardo. / Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. In: Journal of the American Heart Association. 2014 ; Vol. 3, No. 5.
@article{10c862942e3e42db9b9e59d45f10dd7b,
title = "Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction",
abstract = "Background-The regenerative potential of cardiosphere-derived cells (CDCs) for ischemic heart disease has been demonstrated in mice, rats, pigs, and a recently completed clinical trial (CADUCEUS). CDCs are CD105+ stromal cells of intrinsic cardiac origin, but the antigenic characteristics of the active fraction remain to be defined. CDCs contain a small minority of c-kit+ cells, which have been argued to be cardiac progenitors, and a variable fraction of CD90+ cells whose bioactivity is unclear. Methods-We performed a retrospective analysis of data from the CADUCEUS trial and a prospective mouse study to elucidate the roles of c-kit+ and CD90+ cells in human CDCs. Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit+ cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). In contrast, CD90 expression negatively correlates with the therapeutic benefit of CDCs in humans (ie, higher CD90 expression associated with lower efficacy). Depletion of CD90+ cells augments the functional potency of CDCs in murine MI. CD90- CDCs secrete lower levels of inflammatory cytokines and can differentiate into cardiomyocytes in vitro and in vivo. Conclusion-The majority population of CDCs (CD105+/CD90-/c-kit-) constitutes the active fraction, both in terms of therapeutic efficacy and in the ability to undergo cardiomyogenic differentiation. The c-kit+ fraction is neither necessary for, nor contributory to, the regenerative efficacy of CDCs.",
keywords = "Cardiosphere-derived cells, CD90, Ckit, Myocardial infarction",
author = "Ke Cheng and Ahmed Ibrahim and Hensley, {M. Taylor} and Deliang Shen and Baiming Sun and Ryan Middleton and Weixin Liu and Smith, {Rachel R.} and Eduardo Marb{\'a}n",
year = "2014",
language = "English (US)",
volume = "3",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction

AU - Cheng, Ke

AU - Ibrahim, Ahmed

AU - Hensley, M. Taylor

AU - Shen, Deliang

AU - Sun, Baiming

AU - Middleton, Ryan

AU - Liu, Weixin

AU - Smith, Rachel R.

AU - Marbán, Eduardo

PY - 2014

Y1 - 2014

N2 - Background-The regenerative potential of cardiosphere-derived cells (CDCs) for ischemic heart disease has been demonstrated in mice, rats, pigs, and a recently completed clinical trial (CADUCEUS). CDCs are CD105+ stromal cells of intrinsic cardiac origin, but the antigenic characteristics of the active fraction remain to be defined. CDCs contain a small minority of c-kit+ cells, which have been argued to be cardiac progenitors, and a variable fraction of CD90+ cells whose bioactivity is unclear. Methods-We performed a retrospective analysis of data from the CADUCEUS trial and a prospective mouse study to elucidate the roles of c-kit+ and CD90+ cells in human CDCs. Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit+ cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). In contrast, CD90 expression negatively correlates with the therapeutic benefit of CDCs in humans (ie, higher CD90 expression associated with lower efficacy). Depletion of CD90+ cells augments the functional potency of CDCs in murine MI. CD90- CDCs secrete lower levels of inflammatory cytokines and can differentiate into cardiomyocytes in vitro and in vivo. Conclusion-The majority population of CDCs (CD105+/CD90-/c-kit-) constitutes the active fraction, both in terms of therapeutic efficacy and in the ability to undergo cardiomyogenic differentiation. The c-kit+ fraction is neither necessary for, nor contributory to, the regenerative efficacy of CDCs.

AB - Background-The regenerative potential of cardiosphere-derived cells (CDCs) for ischemic heart disease has been demonstrated in mice, rats, pigs, and a recently completed clinical trial (CADUCEUS). CDCs are CD105+ stromal cells of intrinsic cardiac origin, but the antigenic characteristics of the active fraction remain to be defined. CDCs contain a small minority of c-kit+ cells, which have been argued to be cardiac progenitors, and a variable fraction of CD90+ cells whose bioactivity is unclear. Methods-We performed a retrospective analysis of data from the CADUCEUS trial and a prospective mouse study to elucidate the roles of c-kit+ and CD90+ cells in human CDCs. Here, we show, surprisingly, that c-kit expression has no relationship to CDCs' therapeutic efficacy in humans, and depletion of c-kit+ cells does not undermine the structural and functional benefits of CDCs in a mouse model of myocardial infarction (MI). In contrast, CD90 expression negatively correlates with the therapeutic benefit of CDCs in humans (ie, higher CD90 expression associated with lower efficacy). Depletion of CD90+ cells augments the functional potency of CDCs in murine MI. CD90- CDCs secrete lower levels of inflammatory cytokines and can differentiate into cardiomyocytes in vitro and in vivo. Conclusion-The majority population of CDCs (CD105+/CD90-/c-kit-) constitutes the active fraction, both in terms of therapeutic efficacy and in the ability to undergo cardiomyogenic differentiation. The c-kit+ fraction is neither necessary for, nor contributory to, the regenerative efficacy of CDCs.

KW - Cardiosphere-derived cells

KW - CD90

KW - Ckit

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84913600832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913600832&partnerID=8YFLogxK

M3 - Article

C2 - 25300435

AN - SCOPUS:84913600832

VL - 3

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 5

M1 - e001260

ER -